OMDA Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $78 million, up 42% year-over-year.
Net Loss: Narrowed to $3 million from $9 million in Q1 2025.
Adjusted EBITDA: Positive at $1 million, an improvement of $5 million year-over-year.
Gross Margin: GAAP gross margin at 62%, up from 58% in Q1 2025; non-GAAP gross margin at 64%, up from 60%.
Total Members: Surpassed 1 million, reaching 1,025,000, a 51% increase year-over-year.

2. Strategic Updates and Business Highlights

Growth Levers: Focus on expanding reach through partnerships with pharmacy benefit managers (PBMs), increasing enrollment, enhancing member engagement via AI tools, and improving operational efficiency.
GLP-1 Initiatives: Collaboration with Optum Rx and Eli Lilly to enhance access to GLP-1 medications, marking a significant expansion in prescribing capabilities.
Multi-Condition Programs: Strong enrollment growth in diabetes and hypertension programs, with multi-condition close rates remaining robust at 40-50%.
AI Integration: Implementation of AI tools in care delivery and operations, enhancing productivity and member experience.
Clinical Evidence: Continued publication of peer-reviewed studies, reinforcing the effectiveness of Omada’s programs.

3. Forward Guidance and Outlook

Revenue Guidance: Raised to $322 million - $330 million for the full year, up from $312 million - $322 million.
Adjusted EBITDA Guidance: Increased to $14 million - $20 million, up from $7 million - $15 million.
Growth Expectations: Anticipated continued momentum from new commercial relationships and program launches, with expectations for revenue contributions from new offerings to ramp up in 2027.

4. Bad News, Challenges, or Points of Concern

Impact from Global Events: Minor impact from the conflict in Iran, leading to increased device-related costs, estimated at $1 million for the year.
Revenue Per Member Dynamics: While revenue per member may decline in the second and third years of membership, gross profit per member is expected to increase, indicating a shift in member composition.
Competitive Landscape: The presence of multiple vendors in the GLP-1 space may pose challenges in gaining market share and mind share among employers.

5. Notable Q&A Insights

GLP-1 Market Interest: There is growing interest among employers for diverse GLP-1 benefit designs, with Omada positioned to cater to various employer needs.
Retention Rates: Improvements in member retention rates were noted, with members staying longer in programs, particularly in multi-condition offerings.
Cholesterol Program: The cholesterol program is gaining traction, with several large clients signed on, reflecting strong demand for cardiometabolic solutions.
AI Tools Feedback: Positive feedback on AI-driven features like Meal Map, which have shown to enhance member engagement and tracking.

This summary encapsulates the key aspects of Omada Health's Q1 2026 earnings call, highlighting financial performance, strategic initiatives, future outlook, and notable insights from the Q&A session.

OMDA — Omada Health